ArticleJTO clinical and research reports2025
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.
Valérie Gounant et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.